A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

147

Participants

Timeline

Start Date

April 10, 2020

Primary Completion Date

March 31, 2021

Study Completion Date

March 17, 2022

Conditions
Spondyloarthritis
Interventions
DRUG

Ixekizumab

Administered SC

DRUG

Placebo

Administered SC

Trial Locations (19)

20040

HuaShan Hospital Affiliated To Fudan University, Shanghai

100034

Peking University First Hospital, Beijing

100730

Beijing Hospital, Beijing

210000

Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School, Nanjing

210029

Jiangsu Province Hospital, Nanjing

230001

Anhui Provincial Hospital, Hefei

233004

Afflilated Hospital of Bengbu Medical College, Bengbu

310009

The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

337000

Pingxiang People's Hospital, Pingxiang

412007

ZhuZhou Central Hospital, Zhuzhou

430022

Wuhan Union Hospital, Wuhan

430030

Wu Han Tongji Hospital, Wuhan

510120

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou

515041

1st Hospital affiliated to Medical College of Shantou Univer, Shantou

518020

Shenzhen People's Hospital, Shenzhen

610041

West China Hospital Sichuan University, Chengdu

650032

First Affiliated Hospital of Kunming Medical University, Kunming

830001

People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi

014000

The First Affiliated Hospital of Baotou Medical College, Baotou

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04285229 - A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis | Biotech Hunter | Biotech Hunter